MedTrace Logo

Antihistamines in Eosinophilic Esophagitis

NCT04248712 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-12-20

Study results available
· View outcomes & findings →

Summary

Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

Famotidine

40 mg tab twice daily by mouth for 12 week duration

DRUG

Loratadine

10 mg tab once daily by mouth for 12 week duration

DRUG

Placebo

Contains no active ingredient

Sponsors & Collaborators

Principal Investigators

  • Dawn Francis, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04248712 on ClinicalTrials.gov